$NGTF “Nightfood Holdings expands its AI-powered robotics

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

NORBIT Secures Significant NOK 120 Million Defence Order NORBIT has recently made an exciting announcement regarding a significant contract within its segment PIR. The company has been awarded a manufacturing order valued at NOK 120 million from a European client specializing in defence and security. This order is poised for delivery in late 2025 and early 2026, marking a...

Is There Smoke Without Fire in Recent Company Mergers? Well, here we go again. It seems every time deals like these pop up, questions start flying about fairness and insider scoops. The big fish here? The Brink's Company (NYSE:BCO), Select Medical Holdings Corporation (NYSE:SEM), and NCR Atleos Corporation (NYSE:NATL). Halper Sadeh LLC, the investor rights firm, is on a...

Significant Insider Transaction at TG Therapeutics Recently, an important transaction came to light involving Yann Echelard, Director at TG Therapeutics (NASDAQ:TGTX). The details were revealed through the latest SEC filing. On a given date, Echelard sold 5,000 shares, raising a total of $162,850. Such insider trading can often prompt discussions regarding the company’s...

MasonMade Ventures Launches to Revamp Facilities Management Serial Entrepreneurs Aim to Disrupt the FM Industry through Innovative Software Solutions and Expert Trades MasonMade Ventures, established by visionary entrepreneurs Joseph Scaretta and Moses Carrasco, is set to change the face of facilities management. This operational holding company focuses on investing in...

Kyverna Therapeutics' Upcoming Investor Conferences Kyverna Therapeutics, Inc. (NASDAQ: KYTX), a pioneering clinical-stage biopharmaceutical company committed to innovative cell therapies for autoimmune diseases, is slated to present at a series of significant investor conferences this September. Warner Biddle, the Chief Executive Officer of Kyverna, will be the...